New research from Memorial Sloan Kettering may help prevent C.diff infections. Image: Memorial Sloan Kettering |
According to the Mayo Clinic, for many years there has been
no effective treatment for gastrointestinal inflections. However, new research
from Memorial Sloan Kettering is creating a different strategy that looks to
use a bacterial species that is found in healthy gastrointestinal tracts to
prevent C.diff infections.
Eric Pamer, the Head of the Division of General
Medicine and Chief of MSK’s Infectious Diseases Service, stated, “It’s been
well appreciated that the loss of normal bacteria in the intestines can lead to
infection with C. diff. Now that we
know which bacterial species has a protective effect, we can begin to look for
ways to develop a clinical treatment,” of advancements being made.
Researchers have known for years that treatment with antibiotics
can damage bacterial strains that are beneficial in the intestines and thus
allow C.diff to continue growing and
damage the body. Recent studies have shown that fecal transplants—where
uninfected feces are transplanted to the colon of someone with C.diff.—can lead
to a suppression of C.diff infections.
The research conducted at Memorial Sloan Kettering was aided
by a generous gift of $100 million from the Marie-Josée and Henry R. Kravis
Foundation, which sought to bring financial aid to cancer biology, bioinformatics,
pathology and systems biology. The Marie-Josée and Henry R. Kravis Center for Molecular Oncology
(CMO) undertook an endeavor to help with the research of cancer through genomic
analysis of patient-derived tumors. It’s due to such contributions that
Memorial Sloan Kettering aims to reach the ambitious goal of expediting and
streamlining cancer genomics research to guide cancer treatments, and is what
makes it a leader in other health research fields.
No comments:
Post a Comment